print-logo
Logo
  • Healthcare Consultants
  • Healthcare Managers
  • Who we are Arrow Down
    • About us
    • Our purpose & values
    • Our team
    • News & events
  • What we do Arrow Down
    • Overview
    • Market Access
    • Medical Affairs
    • Government Affairs
    • Commercial
    • Patient Advocacy
    • Lifecycle Management
  • Insights Arrow Down
    • Publications
    • Project cases
    • Early Asset Strategy
    • Value Pull-Through
    • Environment Transformation
  • Careers Arrow Down
    • Why join us
    • Open positions
    • Career paths
    • FAQ
  • Contact
  • Search Icon
  • Healthcare Consultants
  • Healthcare Managers
  • Search Icon
  • Search
Back to Publications
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon
  • download

Patient evidence in HTA: Does it matter?

Results of global surveys of payers, patient experts and pharmaceutical company employees shine a light on how the use of patient evidence can be optimized to ensure the patient voice is heard in HTA/access decision-making

Report on Patient Evidence in HTA / Access decision-making

Despite growing acceptance around the importance of patient input and evidence in healthcare decision-making overall, there still seems to be inconsistency when it comes to the acceptance of patient evidence in HTA/access decisions. In recent surveys of payers, patient experts trained on HTA and pharmaceutical company employees: 

38% of payers said that patient evidence is either often or always considered in HTA-access decisions in their country

A key reason seems to be the persistent perception among many payers that patient evidence (e.g. PROs) is subjective and qualitative, while the HTA process is the opposite. Patient experts, pharma and payer survey respondents all agreed that patient evidence should be more systematically included in HTA/access decision-making, but how can this be achieved in a way that overcomes existing concerns?

The majority of survey respondents agreed that pharma needs to play a key role in facilitating the incorporation of patient evidence in decision-making. We have identified 5 ways for Pharma to elevate patient evidence to achieve more balanced HTA/access decision-making – in partnership with patient communities and HTA/access stakeholders:

Educating and elevating - Building trust - Generating robust evidence - Enabling early co-creation - Demonstrating impact

Ensuring patients are involved earlier to develop more meaningful patient evidence for consideration at HTA/access decision-making will benefit all stakeholders. For pharma, clinical programs will be focused on what really matters to patients, increasing the likelihood of developing truly impactful treatments and meeting unmet needs. For payers, they will have a more complete picture of what constitutes value to patients, assisting with difficult decisions on spending priorities. And for patients, they will be empowered and ultimately benefit from improved access to potentially transformational medicines. 

For all stakeholders, the systematic integration of patient evidence into HTA/access decision-making provides an opportunity to break down silos and build long lasting relationships so at last, when patients talk, they are truly heard.


Download the full report on patient evidence in HTA here. 

Download PDF 1.5 MB

Contact our experts

Veronica Al-Saifi

Veronica Al-Saifi

Senior Consultant

mail_icon linkedin_icon
Merlin Williams

Merlin Williams

Manager

mail_icon linkedin_icon
Daniela Gödderz

Daniela Gödderz

Director

mail_icon linkedin_icon
Meike Wenzel

Meike Wenzel

Partner

mail_icon linkedin_icon
Andrea Sobrio

Andrea Sobrio

Founder and Managing Partner

mail_icon linkedin_icon

Related Publications

Publication Preview Image

December 16 2021

All PROs, no cons? Why patient-reported outcomes can ensure the patient voice is fully heard in access decisions

Publication Preview Image

October 10 2016

Orphan drugs – leading the way in patient centricity

Publication Preview Image

March 21 2017

Engaging patients right from the start

Publication Preview Image

May 29 2017

Power to the people

Publication Preview Image

May 12 2021

Product launches: making the most of your one shot

Publication Preview Image

September 09 2020

Patient centricity standards, criteria and KPIs across the biopharma industry (Part 2)

Share this page
  • linkedin_icon
  • twitter_icon
  • mail_icon
  • print_icon

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK
arrow_up

How can we help?

Contact us

Our offices

Careers

Footer Logo
  • Who we are
  • What we do
  • Insights
  • Careers
  • Contact
  • Terms of use
  • Privacy policy
  • Imprint

2023 Executive Insight. All rights reserved.